NCT03934736 - HEPLISAV-B® in Adults With End-Stage Renal Disease (ESRD) Undergoing Hemodialysis | Biotech Hunter

Enrollment

119

Participants

Timeline

Start Date

April 22, 2019

Primary Completion Date

October 23, 2020

Study Completion Date

September 15, 2021

Conditions

End Stage Renal Disease on Hemodialysis (Diagnosis)

Interventions

DRUG

HEPLISAV-B®

HEPLISAV-B®, a licensed, commercially-available hepatitis B vaccine for adults 18 years of age and older, consisting of the adjuvant cytidine phosphoguanosine (CpG) 1018 combined with the antigen recombinant hepatitis B surface antigen (rHBsAg).

Trial Locations (20)

10461

DaVita Clinical Research or Affiliate, The Bronx

19106

DaVita Clinical Research or Affiliate, Philadelphia

23510

DaVita Clinical Research or Affiliate, Norfolk

28801

DaVita Clinical Research or Affiliate, Asheville

32789

DaVita Clinical Research or Affiliate, Winter Park

33021

DaVita Clinical Research or Affiliate, Hollywood

33614

DaVita Clinical Research or Affiliate, Tampa

34471

DaVita Clinical Research or Affiliate, Ocala

44718

DaVita Clinical Research or Affiliate, Canton

47130

DaVita Clinical Research or Affiliate, Jeffersonville

48066

DaVita Clinical Research or Affiliate, Roseville

53227

DaVita Clinical Research or Affiliate, Milwaukee

55404

DaVita Clinical Research or Affiliate, Minneapolis

55435

DaVita Clinical Research or Affiliate, Edina

64111

DaVita Clinical Research or Affiliate, Kansas City

78229

DaVita Clinical Research or Affiliate, San Antonio

79902

DaVita Clinical Research or Affiliate, El Paso

89106

DaVita Clinical Research or Affiliate, Las Vegas

06002

DaVita Clinical Research or Affiliate, Bloomfield

06762

DaVita Clinical Research or Affiliate, Middlebury